Can a popular class of diabetes drugs that includes Merck's Januvia help treat COVID-19?

Concept of SARS-CoV-2 or COVID-19
Diabetes meds that inhibit DPP-4 might help some patients with COVID-19, a University of Miami scientist suggests. (Maksim Tkachenko/iStock/Getty Images Plus)

As COVID-19 spread across the globe, scientists are hunting for drugs that could be repurposed as a quick way to tackle the disease. Among them is a University of Miami researcher who has pointed to previous studies of other coronaviruses to back up his suggestion that a class of diabetes medications known as DPP-4 inhibitors might help.

In a commentary published recently in the journal Diabetes Research and Clinical Practice, endocrinologist Gianluca Iacobellis, M.D., Ph.D., argued that the DPP-4 enzyme represents a potential target that deserves further analysis for its role in COVID-19 respiratory disease.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Several DPP-4 inhibitors are already on the market, including Boehringer Ingelheim and Eli Lilly’s Tradjenta, Merck & Co.’s Januvia and the related combo Janumet. Iacobellis suggests that these drugs be tested in clinical trials for their ability to lower inflammation in COVID-19 patients with Type 2 diabetes, a group that’s disproportionally suffering from severe disease.

The DPP-4 enzyme is expressed in many tissues, but perhaps it’s best known for its role in glucose and insulin metabolism. By degrading GLP-1, DPP-4 can reduce insulin secretion. It’s also involved in immune regulation by activating T cells and increasing CD86 expression, Iacobellis said in the article.

In a 2013 Nature study, scientists in the Netherlands identified DPP-4 as a functional receptor for the spike protein of a MERS coronavirus. MERS-CoV binds to the receptor and interacts with T cells and nuclear factors that are involved with inflammatory responses. Both MERS-CoV and the current SARS-CoV-2 use the spike protein on their surfaces to latch onto and infect host cells.

In a 2019 JCI Insight study, scientists at the University of Maryland and Johns Hopkins University developed a mouse model that was susceptible to MERS-CoV by expressing human DPP-4. Upon infection with MERS-CoV, mice fed a high-fat diet that developed a Type 2 diabetes-like condition and suffered from severe symptoms of the infection for a longer period than did control mice.

However, these DPP-4 mice had fewer inflammatory molecules such as monocytes, CD4+ T cells and lower expression of TNF-alpha and IL-6. The researchers speculate that the immune response may have contributed to the more severe manifestation of MERS-CoV in diabetic mice.

RELATED: COVID-19: Bio researchers race to repurpose everything from antiviral to anticancer discoveries

Patients with underlying diseases, including Type 2 diabetes, are at higher risk of serious disease in the current pandemic. Data from the Chinese city of Wuhan and Italy show diabetes patients have accounted for a large proportion of intensive care admission and deaths related to COVID-19.

Other existing drugs have been pushed into COVID-19 clinical trials. Roche is examining its arthritis drug Actemra, and Sanofi and Regeneron are testing their rival IL-6 inhibitor Kevzara. AstraZeneca is preparing to start investigating its BTK blood cancer drug Calquence in the same setting.

DPP-4 inhibition doesn't seem to block viruses. A meta-analysis of 74 studies showed the risk of overall infection was comparable between DPP-4 inhibitor treatment and placebo or active comparator in diabetes patients. And the 2013 Nature study also showed that MERS-CoV infection could not be blocked by Januvia, AstraZeneca’s Onglyza or other DPP-4 inhibitors.

But the use of DPP-4 inhibitors and GLP-1 analogs has been associated with anti-inflammatory effects. Iacobellis argues that might be helpful in helping diabetes patients control COVID-19-related immune overreaction.

All told, DPP-4 “may represent a potential target for preventing and reducing the risk and the progression of the acute respiratory complications that Type 2 diabetes may add to the COVID-19 infection,” Iacobellis wrote in his article.

“The body is overreacting with this inflammatory response to the virus,” he said in a statement. “This could be partially mediated by DPP-4. The virus [potentially] binds to the enzyme and the enzymatic activity of DPP4 overexpresses inflammatory cytokines, exaggerating the inflammatory response.”

Editor's note: Iacobellis' statement at the bottom of the story has been editorially added "potentially" to reflect that the interaction between the COVID-19 spike glycoprotein and DPP-4 is a prediction based on scientific research, not a proven fact.

Suggested Articles

The Tel Aviv-based VC firm focused on digital health has closed a new fund totaling $170 million, with plans to expand to the Asia Pacific region.

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.